Our Story
The families who participate in the Children's Brain Tumor Project (CBTP) are personally invested in finding new treatment options -- and ultimately cures -- for rare and inoperable brain tumors in children and young adults. These tumors, including DIPG, gliomatosis cerebri, and AT/RT, occur so rarely that they do not get the major funding or attention that research scientists need to find a cure. But for families affected by them, every case is one too many.
The CBTP is funded in large part by a network of families who have lost loved ones to these terrible tumors, or whose families have been threatened by such a diagnosis. These family foundations and their supporters drive funding, advocacy and awareness for CBTP.
Dr. Mark Souweidane and Dr. Jeffrey Greenfield, Co-Directors of the CBTP at Weill Cornell, have pioneered a neuroscientific paradigm using genomic sequencing and Convection Enhanced Delivery (CED). A Phase I clinical trial is testing the safety of using (CED) to deliver a low-toxicity drug cocktail directly to the tumor site. Bench researchers are using genomic sequencing to identify genetic mutations in each patient's tumor to identify the best drugs to combat them, and investigating new ways to stop tumor progression by blocking signals from bone marrow.
